**Supplementary Table S7. Follow up of children* exposed to immunosuppressive medications in 2nd and/or 3rd trimester of pregnancy,**

**SLR period 2006-2015**

<table>
<thead>
<tr>
<th>Maternal medication in pregnancy</th>
<th>Type of publication in numbers</th>
<th>References</th>
<th>Number of children</th>
<th>Mean follow up time and range: years (yrs)</th>
<th>Number of children vaccinated / children with normal vaccination response</th>
<th>Rate of serious infection in 1st year of life compared to non-exposed children</th>
<th>Physical development: Number of children normal/impaired</th>
<th>Cognitive development: Number of children normal/impaired</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab</td>
<td>2 cohorts (2 abstracts) 2 case-controls 7 case-reports</td>
<td>[1-11]</td>
<td>269</td>
<td>1.1 (4 mo.-3yrs)</td>
<td>49/48</td>
<td>Not increased</td>
<td>57/0</td>
<td>22/0</td>
<td>1 child died after BCG vaccination at 3 months of age</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>2 cohorts (2 abstracts) 2 case-controls 3 case-reports</td>
<td>[1,4,7-9,12,13]</td>
<td>136</td>
<td>1.2 (5 mo.-2.2 yrs)</td>
<td>3/3</td>
<td>Not increased</td>
<td>15/1</td>
<td>3/0</td>
<td></td>
</tr>
<tr>
<td>Certolizumab</td>
<td>2 cohorts (2 abstracts)</td>
<td>[7,8]</td>
<td>99</td>
<td>1.0</td>
<td>Not reported</td>
<td>Not increased</td>
<td>10/0</td>
<td>Not studied</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>9 case-reports</td>
<td>[1,14-21]</td>
<td>8</td>
<td>1.4 (6 mo.-4.5yrs)</td>
<td>5/5</td>
<td>Not reported</td>
<td>8/0</td>
<td>2/0</td>
<td>Transient B cell depletion in children exposed in 2nd and 3rd trimester</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>1 cohort</td>
<td>[22]</td>
<td>39</td>
<td>Mean not reported. (7 mo.-3 yrs)</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>39/0</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>1 cohort 2 case-controls</td>
<td>[23-25]</td>
<td>58</td>
<td>4.5 yrs (6 mo.-9.2 yrs)</td>
<td>45/45</td>
<td>Not increased</td>
<td>45/0</td>
<td>58/7</td>
<td></td>
</tr>
<tr>
<td>Dexamethason</td>
<td>2 cohorts</td>
<td>[26,27]</td>
<td>27</td>
<td>6 (1.8-11 yrs)</td>
<td>Not reported</td>
<td>Not reported</td>
<td>11/0</td>
<td>27/0</td>
<td></td>
</tr>
</tbody>
</table>
1 Included only if total number of children exposed to a medication > 5

1 According to National vaccination programs, including measles, mumps, rubella, pertussis, tetanus, diphtheria, hepatitis B, poliomyelitis. In some countries live vaccines BCG vaccine is given at 3 months and rotavirus at 2, 4, and 6 months of age

2 Serious infection defined as requiring intravenous treatment or hospitalization

REFERENCES


